Interacting Drugs |
Ketoconazole (systemic) vs Pazopanib |
Security Level |
|
Mechanism |
Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib. |
Management |
Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible. If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg. Further dose reductions may also be required. |
Ketoconazole (systemic) vs Pazopanib
Post Review about Ketoconazole (systemic) vs Pazopanib Click here to cancel reply.
Other Interactions of Pazopanib
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.